💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Memantine

CHEMBL807 Phase 4 Aprovado Small molecule
Half-Life
60-80 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
179.3 g/mol
LogP
3.3
Phase
4

An NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease by blocking excessive glutamate activity that can damage brain cells, helping to improve memory, thinking, and daily functioning. It is often used in combination with cholinesterase inhibitors.

Peso Molecular

179,3080 g/mol

LogP

3,30

TPSA

26,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Osteoporosis Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Melanoma Oncology Systemic Lupus Erythematosus Multiple Sclerosis Stroke Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Classes de Medicamentos

N — N - Nervous System

Mecanismo de Ação

Non-competitive NMDA receptor antagonist.

Pharmacokinetics (PK)

Half-Life 60-80 hours

Pharmacodynamics (PD)

Mecanismo

Non-competitive NMDA receptor antagonist.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC12CC3CC(C)(C1)CC(N)(C3)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C12H21N

                    

                    
                    

                        
HBD / HBA

                        
1 / 1

                    

                    
                    

                        
Ligações Rotacionáveis

                        
0

                    

                    
                    
                    

                        
Átomos Pesados

                        
13

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            GABRA1 (GABA-A Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            HRH1 (Histamine H1 Receptor)
                            Antagonist
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Memantine + Metformin
                            
                        

                        
                        
Memantine may compete with metformin for renal tubular cationic secretion, potentially increasing metformin plasma concentrations modestly.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Memantine + Hydrochlorothiazide
                            
                        

                        
                        
Hydrochlorothiazide may reduce renal clearance of memantine through alkalinisation of urine, as memantine elimination is pH-dependent; the clinical impact is generally minor.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
An NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease by blocking excessive glutamate activity that can damage brain cells, helping to improve memory, thinking, and daily functioning. It is often used in combination with cholinesterase inhibitors.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Non-competitive NMDA receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Memantine: Half-life: 60-80 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Memantine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL807.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4054.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.